Document is current
Any future updates will be listed below
-
Authors
Imai, Noboru
Matsumori, Yasuhiko
- License Information
-
More Information
Article History
Received: 13 March 2024
Accepted: 24 September 2024
First Online: 30 September 2024
Declarations
:
: The authors declare the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article. NI reports being an advisor for Sawai and receiving speaker fees from Daiichi Sankyo, Eli Lilly, Otsuka, and Amgen; however, these companies were not related to the study. YM reports personal consultancy fees from Amgen Astellas BioPharma K.K., Daiichi Sankyo Company Limited, Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co., Ltd. during the conduct of the study; however, no company had any relation to the study.
: This study was conducted at two accredited headache education facilities endorsed by the Japanese Headache Society: the Japanese Red Cross Shizuoka Hospital and the Sendai Headache and Neurology Clinic. This was a two-center prospective investigation of patients with headache disorders. The participants provided informed consent in accordance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects issued by the Japanese Ministry of Health, Labor, and Welfare. This study was approved by the Ethics Committee of the Japanese Red Cross Shizuoka Hospital (reference number: 2018–21).
